Because of the high distribution of this compound in the lung and the potential utility of HDAC inhibitors in treating lung cancer, we explored the potential of GCJ-490A in the treatment of NSCLC in the present study. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.